DISCLAIMER: THE CONTENTS ARE FOR INFORMATION PURPOSES ONLY AND UNDER NO CIRCUMSTANCES MAY CONSTITUTE THE PRESCRIPTION FOR A TREATMENT OR REPLACE THE VISIT SPECIALIST OR THE DIRECT RELATIONSHIP WITH YOUR VETERINARY / MEDICAL. YOU DO NOT HAVE TO USE THE TERMS CONTAINED IN THESE PAGES FOR DIAGNOSTIC PURPOSES OR prescriptive OR AS THE BASIS FOR ANY MEDICAL THERAPY. ANY DECISIONS THAT SHOULD BE TAKEN BY YOU BASED ON HERE READ IN INFORMATION, ARE ASSUMED IN FULL AUTONOMY DECISION-MAKING AND RISK. ALL INFORMATION HEREIN ARE DERIVED FROM SOURCES BIBLIOGRAPHIC, PERSONAL EXPERIENCES AND CLINICAL STUDIES OF PUBLIC DOMAIN, they ARE FOR INFORMATIONAL PURPOSES ONLY, WITHOUT BEING IN ANY WAY LEGALLY LIABLE AND THEREFORE DOES NOT ACCEPT RESPONSIBILITY FOR ANY DAMAGES THAT MAY RESULT FROM THE USE OF THIS INFORMATION. WE SHALL HAVE NO LIABILITY FOR ANY ERRORS OF TEXT
 

Copyright (c) Elicats – All rights reserved. Prohibited the partial copy.

Bibliography

1. Kittleson MD, Meurs KM, Munro MJ, Kittleson JA, Liu SK, Pion PD, Towbin JA. Familial hypertrophic cardiomyopathy in Maine Coon cats: an animal model of human disease. Circulation. 1999 Jun 22; 99 (24): 3172-80.

den Toom, ML, et al. “Effects of clopidogrel therapy on whole blood platelet aggregation, the Plateletworks® assay and coagulation parameters in asymptomatic cats with hypertrophic cardiomyopathy: a pilot study.” Veterinary Quarterly 37.1 (2017): 8-15.

Orenes-Pinero, Esteban, et al. “An insight of novel pharmacological therapies for hypertrophic cardiomyopathy.” Medicinal Chemistry 7.4 (2011): 275-285.

Ferasin L, T. DeFrancesco Management of acute heart failure in cats. Journal of veterinary cardiology. 2015; 17 Suppl 1: S173-189.

 Hanzlíček AS, R Gehring, Kukanich B, Kukanich KS, Borgarelli M, N Smee, Olson EE, Margiocco M. Pharmacokinetics of oral pimobendan in healthy cats. Journal of veterinary cardiology. 2012; 14: 489-496.

Jackson, Bethany L., B. Darcy Adin, and Linda B. Lehmkuhl. “Effect of atenolol on heart rate, arrhythmias, blood pressure, and dynamic left ventricular outflow tract obstruction in cats with subclinical hypertrophic cardiomyopathy.” Journal of Veterinary Cardiology 17 (2015): S296-S305.

Schober, Karsten E., et al. “Effect of treatment with atenolol on 5-year survival in cats with preclinical (asymptomatic) hypertrophic cardiomyopathy.” Journal of veterinary cardiology 15.2 (2013): 93-104.

Marian, Ali J. “Update on hypertrophic cardiomyopathy.” Texas Heart Institute Journal 37.3 (2010): 322.
Wilder, T. (2014). Tropomyosin Phosphorylation and Oxidative Stress in Hypertrophic Cardiomyopathy (Doctoral dissertation, University of Illinois at Chicago).
Pouchelon, JL, et al. “Cardiovascular-renal axis disorders in the domestic dog and cat: a veterinary consensus statement.” Journal of small animal practices 56.9 (2015): 537-552.
Lombardi, Raffaella, et al. “Treatment With Anti-oxidant N-acetylcysteine ​​attenuates Cardiac Hypertrophy And Fibrosis And Susceptibility To Improves Cardiac Arrhythmias In The β-myosin heavy chain-Q403 Transgenic Rabbit Model Of Human Hypertrophic Cardiomyopathy.” 116.Suppl Circulation 16 (2007): II_177-II_177 .
Wilder, Tanganyika, et al. “N-acetylcysteine ​​reverses hypertrophy and diastolic dysfunction in familial hypertrophic cardiomyopathy.” American Journal of Physiology-Heart and Circulatory Physiology 309.10 (2015): H1720-H1730.
Rajapakse, Niwanthi, et al. “N-acetylcysteine ​​reverses established cardiac and renal fibrosis in a mouse model of heart failure.” The FASEB Journal Supplement 30.1 (2016): 735-4.
Sen-Chowdhry, Srijita, et al. “Update on hypertrophic cardiomyopathy and a guide to the guidelines.” Nature Reviews Cardiology 13:11 (2016): 651-675.